Imagine using a high-energy beam, like a super-powered X-ray, to chop up egg proteins into tiny, active pieces. These tiny pieces act like natural shields that kill bacteria without using traditional antibiotics. The project turns egg industry waste, like shells, into high-value medical bandages and smart food wraps.
Antimicrobial resistance is a growing global crisis, with predicted deaths reaching 10 million by 2050. There is an urgent need for antimicrobial agents that do not contribute to multi-drug resistance.
A database connecting bioactivity, chemical structure, and processing conditions, along with two prototypes: antimicrobial hydrogel wound dressings and active food packaging films.
If you are a wound care manufacturer dealing with antibiotic-resistant infections—this project developed peptide-laden antimicrobial hydrogel wound dressings that provide a defense against microbial infections.
If you are a packaging producer dealing with food spoilage—this project developed peptide-grafted active food packaging films that use egg-derived peptides to inhibit bacterial growth.
If you are a biotech firm dealing with the high cost of synthetic peptide production—this project developed a method using e-beam accelerators to produce bioactive peptides from abundant egg industry waste streams.
Based on available project data, specific costs for the e-beam process or production are not provided.
The project started with laboratory-scale production and aims to demonstrate the broad scope of applications through product prototypes, but full industrial scale-up data is not yet detailed.
Based on available project data, there is no specific information regarding IP ownership or licensing agreements.
The project focuses on creating peptide-grafted active films, which would serve as the raw material for packaging manufacturers.
The project period runs from 2022-09-01 to 2026-08-31, suggesting that prototypes are being developed during this window.
The consortium consists of 9 partners across 5 countries (IT, PL, PT, SE, UK). It features a balanced mix of 3 industry partners, 3 universities, and 3 research institutes, resulting in a 33% industry ratio. This structure suggests a strong bridge between fundamental radiation research and commercial application.
Contact the Instytut Chemii i Techniki Jadrowej in Poland
Contact us to find licensing opportunities for radiation-induced peptide production.
